Sunil Reddy
YOU?
Author Swipe
View article: Molecularly Targeted Cancer Medications and Kidney Health
Molecularly Targeted Cancer Medications and Kidney Health Open
Importance Oral molecularly targeted cancer medications are widely used. Product labels describe an increase in serum creatinine (sCr), potentially due to reversible inhibition of tubular creatinine secretion rather than acute kidney injur…
View article: EXTH-117. Bitopic inhibitors of mTORC1 cooperate with inhibitors of mitogen-activated protein kinase kinase to drive cytotoxicity in glioblastoma
EXTH-117. Bitopic inhibitors of mTORC1 cooperate with inhibitors of mitogen-activated protein kinase kinase to drive cytotoxicity in glioblastoma Open
We previously described RapaLink-1, a bisteric mTORC1 inhibitor that links the allosteric mTORC1 inhibitor rapamycin to the mTOR kinase inhibitor sapanisertib. RapaLink-1 showed increased efficacy compared to either parent inhibitor in ort…
View article: Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy Open
cTnI surveillance integrated with symptom-based triaging can facilitate early intervention and treatment of cardiotoxicities such as myocarditis.
View article: 67eP Mutational landscape of endometrial carcinoma in India: Lessons learnt from histology to molecular classification
67eP Mutational landscape of endometrial carcinoma in India: Lessons learnt from histology to molecular classification Open
View article: An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma Open
View article: Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec
Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec Open
View article: Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response
Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response Open
View article: A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma
A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma Open
Cytomegalovirus (CMV) reactivation is a rare complication in patients treated with immune checkpoint inhibitors (ICIs), typically occurring after immunosuppressive therapy for immune‐related adverse events (irAEs). Here, we report a unique…
View article: Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response
Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response Open
Despite modern advancements in systemic therapies, melanoma remains a highly malignant cancer, with persistent resistance to therapies such as checkpoint inhibitors and inhibitors of mutated BRAF V600E. Current therapy for targeting metast…
View article: 1469 Hepatic artery pressure enabled drug delivery (PEDD) of nelitolimod combined with checkpoint inhibition (ICI) in uveal melanoma liver metastases (UM-LM) in ICI-naïve and -refractory patients (pts)
1469 Hepatic artery pressure enabled drug delivery (PEDD) of nelitolimod combined with checkpoint inhibition (ICI) in uveal melanoma liver metastases (UM-LM) in ICI-naïve and -refractory patients (pts) Open
View article: PE016 Functional and oncological outcomes of very large prostate sizes post robotic radical prostatectomy
PE016 Functional and oncological outcomes of very large prostate sizes post robotic radical prostatectomy Open
View article: Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications Open
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer with a 40% recurrence rate, lacking effective prognostic biomarkers and surveillance methods. This prospective, multicenter, observational study aimed to evaluate circulating…
View article: Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study Open
View article: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study Open
View article: Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec Open
View article: THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY
THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY Open
Purpose Immune checkpoint inhibitors (ICI) used as cancer therapy have been associated with a range of cardiac immune-related adverse events (irAEs), including fulminant myocarditis with a high case fatality rate. Early detection through c…
View article: A Novel Intersection - Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient with Advanced Cutaneous Squamous Cell Carcinoma: a Case Report
A Novel Intersection - Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient with Advanced Cutaneous Squamous Cell Carcinoma: a Case Report Open
Background Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment. While effective, these therapies sometimes result in immune-related adverse events and have been associated with infectious complicat…
View article: 622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma
622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma Open
Background Although survival remains significantly poorer for thick, ulcerated melanoma, application of immunotherapy is controversial in the absence of nodal disease. Talimogene Laherparpvec (TVEC) is the only FDA approved intralesional t…
View article: 1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial
1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial Open
Background MUM-LM are resistant to ICIs for several reasons including the prevalence of myeloid-derived suppressor cells (MDSCs). PFS has been limited, even with approved therapies such as tebentafusp (median 3.3 months) with grade 3/4 AE …
View article: ESC Cardio-Oncology Guidelines
ESC Cardio-Oncology Guidelines Open
View article: Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma Open
Purpose/Objectives Combination BRAF (vemurafenib, dabrafenib, or encorafenib) plus MEK (trametinib, cobimetinib, or binimetinib) inhibitor therapy is now widely used in the treatment of metastatic melanoma. However, data for intracranial r…
View article: Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020
Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020 Open
Background Widespread implementation of immune checkpoint inhibitors (ICI) and targeted therapies for metastatic melanoma has led to a decline in melanoma-related mortality but increased healthcare costs. We aimed to determine how healthca…
View article: Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry Open
View article: Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis Open
Background: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used to activate the immune system against tumor cells. Despite therapeutic benefits, ICIs have the potential to cause immune-related adverse events such as myocardi…
View article: Traffic Management For Cities
Traffic Management For Cities Open
Most Urban places across the world have considerable traffic congestion, which has become a nightmare for the locals. It is caused by incorrect traffic flagging planning, delayed flagging, and other factors. Traffic light postponement is h…
View article: Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology Open
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related T…
View article: Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient Open
View article: Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma Open
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The …
View article: Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors
Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors Open
View article: Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk Open